Acorda Picks Up Late-Stage Parkinson's Candidate With $363m Biotie Buy
This article was originally published in Scrip
Executive Summary
Acorda Therapeutics Inc.'s president and CEO Ron Cohen has been dropping hints for some months that he was pursuing significant business development opportunities and the EU was his preferred hunting ground. Finally, on Jan. 19, Acorda said it has agreed to acquire Biotie Therapies Corp. of Finland for around $363m. Biotie has a Parkinson's disease drug candidate in Phase III which has a mechanism of action that has caused problems for other companies.
You may also be interested in...
Acorda Investor Scopia Seeks Big Return From Sale Of The Company
Citing recent deals, hedge fund Scopia encouraged Acorda's board on Aug. 7 to pursue a sale, but the company believes its new strategy focused on Parkinson's disease is best for shareholders.
Finance Watch: Second Quarter Begins With Solid Base For Biopharma VC, Shaky Ground For Acorda
First quarter VC investments in biopharma set high expectations for the second quarter; Acorda cuts jobs after patent litigation defeat, plus other strategic realignments; no new US IPOs, but Europe has three; and notable follow-on offerings.
Deep Breath For Acorda As It Prepares Inhaled Levodopa Filing
Acorda's $525m purchase of Civitas in 2014 is now set to bear fruit, with new Phase III data for an inhaled formulation of levodopa, the main attraction of the deal, looking strong enough both to warrant approval filings and please payors.